Log In
BCIQ
Print this Print this
 

Xofigo (Radium-223) (BAY88-8223) (formerly Alpharadin)

  Manage Alerts
Collapse Summary General Information
Company Bayer AG
DescriptionRadiopharmaceutical based on the alpha particle emitter radium-223
Molecular Target Not available
Mechanism of ActionRadiation sensitizer
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$3,197.0M

$2,460.4M

$736.6M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/03/2014

$2,400.0M

$2,400.0M

0

09/07/2009

$797.0M

$60.4M

$736.6M

Get a free BioCentury trial today